scholarly journals COVID-19 Vaccine-Related Axillary Lymphadenopathy in Breast Cancer Patients: Case Series with a Review of Literature

Author(s):  
Jihe Lim ◽  
Seun Ah Lee ◽  
Eun Kyung Khil ◽  
Sun-Ju Byeon ◽  
Hee Joon Kang ◽  
...  
2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Sara Rehman ◽  
Muhammad Atif Naveed

Introduction: Breast cancer is the most common malignancy in women. It frequently metastasizes to bones, lungs and liver. Although rare, skin metastasis may also take place. It may also be the presenting feature of initial or recurrent breast cancer. The assessment of recurrent metastatic disease involving skin after mastectomy can be challenging because of the benign-appearing clinical presentation. The purpose of this caseseries was to explore the clinical and radiological presentation of skin metastasis in patients of breast cancer. Materials and Methods: This is a retrospective case series of breast cancer patients with skin lesions on chest and abdomen at the time of initial presentation, or post-treatment such as, after mastectomy or breast conservation therapy; who underwent various radiological investigations including mammography, ultrasoundscan, computed tomography (CT) scan and magnetic resonance imaging from 1 May 2018 to 30 September 2019 at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Pakistan. Results: A total of eightcases were identified, out of which seven were females. The most common presentation consisted of the presence of metastatic nodules which were seen in 62.5% (five out of eight) of the patients. Other features consisted of erythematous or plaque-like skin thickening on clinical examination, increased density with indistinct margins seen on a mammogram and diffuse oedematous changes in the skin with small irregular mass or infiltration into subcutaneous tissues were visualised on ultrasound and CT studies. Conclusion: Skin metastasis from breast cancer most commonly presents as nodules, although rarely they may present as plaques or diffuse skin thickening. Awareness of diverse manifestations of skin metastasis is of utmost importance in early diagnosis and management.


2015 ◽  
Vol 26 ◽  
pp. vi19
Author(s):  
L. Mercatali ◽  
N. Masalu ◽  
A. Bongiovanni ◽  
A. Pangan ◽  
R. Tedaldi ◽  
...  

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Erika Matos ◽  
Tanja Ovcaricek

Abstract Background Pregnancy associated breast cancer is a rare disease. It presents a unique entity of breast cancer with aggressive phenotype. The main aim was to evaluate how the international guidelines were followed in daily practice. Patients and methods Data concerning patients’ and tumours’ characteristics, management, delivery and maternal outcome were recorded from institutional electronic database. In this paper a case series of pregnant breast cancer patients treated at single tertiary institution between 2007 and 2019 are presented and the key recommendations on managing such patients are summarized. Results Fourteen patients met the search criteria. The majority of tumours were high grade, triple negative or HER2 positive, two patients were de novo metastatic. Treatment plan was made for each patient by multidisciplinary team. Eight patients were treated with systemic chemotherapy with no excess toxicity or severe maternal/fetal adverse effects. In all but two patients, delivery was on term and without major complications. Only one event, which was not in whole accordance with international guidelines, was identified. It was the use of blue dye in one patient. Conclusions Women with pregnancy associated breast cancer should be managed like non-pregnant breast cancer patients and should expect a similar outcome, without causing harm to the unborn child. To achieve a good outcome in pregnancy associated breast cancer, a multidisciplinary approach is mandatory.


2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi10-vi10
Author(s):  
Priya Kumthekar ◽  
Barbara Blouw ◽  
Julie Mayer ◽  
Deanna Fisher ◽  
Michael Dugan ◽  
...  

Abstract INTRODUCTION Leptomeningeal Disease (LMD) occurs in 5% of breast cancer patients. Diagnosing LMD remains challenging. Current standard of care has limited sensitivity and is inadequate for monitoring treatment response. Biocept’s CNSide™ is a proprietary assay utilizing a 10-antibody capture cocktail with microfluidic chamber that quantitatively detects tumor cells in the cerebrospinal fluid (CSF). We present a case series using CNSide to manage LMD of 4 unique breast cancer patients treated at three different institutions and demonstrate its impact on clinical management. METHODS Patients were treated at Smilow Cancer Hospital at Yale-New Haven (1 patient), Northwestern Medicine Lou and Jean Malnati Brain Tumor Institute (1 patient) and Barrow Neurological Institute (2 patients). All patients received intrathecal treatment (IT) via an Ommaya Reservoir. CSF tumor cells were detected via cytology and CNSide at diagnosis (3 patients) and throughout treatment (4 patients). RESULTS At diagnosis, CNSide detected tumor cells in 3/3 patients, vs 2/3 patients for cytology. The fourth patient was diagnosed with LMD before CNSide was available. CNSide detected CSF tumor cells in 9/9 (100%) of measurements, vs 4/9 (44%) for cytology for samples analyzed in parallel. Throughout treatment, CNSide was able to track the quantitative LMD response and showed a decrease in CSF tumor cells in all four patients, ranging from 99.7% (from 773 to 2 cells, 1 patient) to 100% (from 4447 to 0 cells; and from 33 to 0 cells, 2 patients). CONCLUSION Intrathecal treatment of LMD via Ommaya reservoir is not widely adopted across the US. Our experience suggests that using CNSide for quantitative CSF tumor cell detection may aid in diagnosing LMD, as well as in quantifying response to treatment particularly in the setting of intrathecal therapy. However, larger prospective clinical trials are needed to establish the role of CNSide in the diagnosis and management of LMD.


2013 ◽  
Vol 21 (10) ◽  
pp. 2679-2686 ◽  
Author(s):  
Ming J. Poi ◽  
Michael Berger ◽  
Maryam Lustberg ◽  
Rachel Layman ◽  
Charles L. Shapiro ◽  
...  

Author(s):  
Pintican Roxana ◽  
Duma Magdalena ◽  
Szep Madalina ◽  
Schiau Calin ◽  
Feier Diana ◽  
...  

Ipsilateral axillary lymphadenopathy related to COVID-19 vaccine was reported as a side effect and started to raise diagnostic dilemmas especially in oncology patients. Breast cancer patients are particularly prone to this benign pitfall that may result in unfortunate management changing or unnecessary biopsy, both causing additional emotional stress for the patients. We present three cases with axillary lymphadenopathy and one with axillary and bilateral supraclavicular lymphadenopathy, and focus on what haven’t been reported yet: the deep and more superior location for the axillary lymphadenopathy and the possibility of contralateral lymphadenopathy secondary to COVID-19 vaccine. Their implication in breast cancer management will also be briefly discussed.


Sign in / Sign up

Export Citation Format

Share Document